genuine question about shortage list that I am slightly embarrassed to ask
The title is the whole question — genuine question about shortage list that I am slightly embarrassed to ask — but here is why I am asking.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
salt forms are the recurring argument and the answer is boring
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Did they name the facility?
[deleted]
What did the intake actually ask you?
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
the API source is the question nobody asks and everybody should
ask which facility, then ask for their testing
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
the label on a compounded vial is a legal document, read it
the label on a compounded vial is a legal document, read it
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
503A or 503B — do you know which?
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
- 1Did they name the facility?10 comments in this branch · started by u/marit_mwangi